Effects of Cranberry on Gut and Metabolic Health

Sponsor
Laval University
Study ID
NCT07460856
Status
Recruiting
Apply to this trial

Conditions

  • Insulin Resistance
  • Metabolic Syndrome
  • Microbiota
  • Overweight/Obesity

Eligibility Criteria

Sex
ALL
Age
25 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Cranberry beverage — DIETARY_SUPPLEMENT
    Daily consumption of 240 ml of cranberry beverage for 12 weeks.
  • Placebo beverage — DIETARY_SUPPLEMENT
    Daily consumption of 240 ml of placebo beverage for 12 weeks.

Study Details

The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored. The primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals. This randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.

Key Dates

First listed
Mar 10, 2026
Start date
Jul 7, 2025
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
73 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION

Arms

  • Experimental: Cranberry beverage
  • Placebo Comparator: Placebo beverage

Primary Outcome Measure

Change in glucose homeostasis [ Time Frame: Pre and post each treatment (12 week/each) ]

Central Contacts

Related Studies